Format

Send to

Choose Destination
J Virol. 2015 May;89(9):4866-79. doi: 10.1128/JVI.03676-14. Epub 2015 Feb 11.

Monoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.

Author information

1
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan fuka@nih.go.jp masuo@phs.osaka-u.ac.jp.
2
Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
3
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan Graduate School of Biological Science, Tokyo University of Science, Chiba, Japan.
4
Life Science Research Laboratories, Wako Pure Chemical Industries, Ltd., Hyogo, Japan.
5
Department of Infectious Diseases, Hamamatsu University School of Medicine, Shizuoka, Japan.
6
Department of Virology II, National Institute of Infectious Diseases, Tokyo, Japan.
7
Department of Biochemistry and Cell Biology, National Institute of Infectious Diseases, Tokyo, Japan.
8
Department of Molecular Pathology, Nara Medical University, Nara, Japan.
9
Laboratory of Bio-Functional Molecular Chemistry, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan fuka@nih.go.jp masuo@phs.osaka-u.ac.jp.

Abstract

Hepatitis C virus (HCV) entry into host cells is a complex process requiring multiple host factors, including claudin-1 (CLDN1). Safe and effective therapeutic entry inhibitors need to be developed. We isolated a human hepatic Huh7.5.1-derived cell mutant that is nonpermissive to HCV, and comparative microarray analysis showed that the mutant was CLDN1 defective. Four hybridomas were obtained, which produced monoclonal antibodies (MAbs) that interacted with the parental Huh7.5.1 cell but not with the CLDN1-defective mutant. All MAbs produced by these hybridomas specifically bound to human CLDN1 with a very high affinity and prevented HCV infection of Huh7.5.1 cells in a dose-dependent manner, without apparent cytotoxicity. Two selected MAbs also inhibited HCV infection of human liver-chimeric mice without significant adverse effects. CLDN1 may be a potential target to prevent HCV infection in vivo. Anti-CLDN1 MAbs may hence be promising candidates as novel anti-HCV agents.

IMPORTANCE:

Safe and effective therapeutic entry inhibitors against hepatitis C virus (HCV) are very useful for combination therapies with other anti-HCV drugs, such as direct-acting antivirals. In this study, we first showed an effective strategy for developing functional monoclonal antibodies (MAbs) against extracellular domains of a multimembrane-spanning target protein, claudin-1 (CLDN1), by using parental cells expressing the intact target membrane protein and target-defective cells. The established MAbs against CLDN1, which had a very high affinity for intact CLDN1, efficiently inhibited in vitro and in vivo HCV infections. These anti-CLDN1 MAbs are promising leads for novel entry inhibitors against HCV.

PMID:
25673725
PMCID:
PMC4403477
DOI:
10.1128/JVI.03676-14
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center